





FUND FEATURES: (Data as on 30th April'22)

Category: Large Cap Monthly Avg AUM: ₹ 1,018.67 Crores Inception Date: 9th June 2006 Fund Manager: Mr. Sumit Agrawal & Mr. Sachin Relekar (w.e.f. 1st March 2022)

Other Parameters: Beta: 0.88 R Squared: 0.95 Standard Deviation (Annualized): 19.33% Benchmark: S&P BSE 100 TRI

(w.e.f. 18/04/2017)

Minimum Investment Amount: ₹5,000/and any amount thereafter.

Exit Load:

- If redeemed/switched out within 365 days from the date of allotment:
 - > Up to 10% of investment: Nil,
 - > For remaining investment: 1% of applicable NAV
- If redeemed / switched out after 365 days from date of allotment: Nil. (w.e.f. 25th June 2021)

SIP Frequency: Monthly (Investor may choose any day of the month except 29th, 30th and 31st as the date of instalment.) Options Available: Growth, IDCW[®] (Payout,

Reinvestment and Sweep (from Equity Schemes to Debt Schemes only))

PLAN	IDCW® RECORD DATE	₹/UNIT	NAV
REGULAR	22-Jul-21	0.89	17.8600
	16-Mar-20	1.04	12.1800
	19-Mar-19	0.77	15.1200
	22-Jul-21	1.11	22.3200
DIRECT	16-Mar-20	1.27	14.9900
	19-Mar-19	0.95	18.4400

Face Value per Unit (in ₹) is 10

Income Distribution cum capital withdrawal is not guaranteed and past performance may or may not be sustained in future. Pursuant to payment of Income Distribution cum capital withdrawal, the NAV of the scheme would fall to the extent of payout and statutory levy (as applicable). @Income Distribution cum capital withdrawal

IDFC LARGE CAP FUND

Large Cap Fund - An open ended equity scheme predominantly investing in large cap stocks

FUND PHILOSOPHY*

The fund aims to generate steady returns by investing in the leading stocks of the chosen sectors, predominantly amongst the large cap universe. The portfolio approach is based on a robust three pillar strategy, namely:

Buying the right sectors – Identifying and investing in the right sectors with the flexibility to have large deviations from the benchmark sector weights.

Buying the sector leaders - Investing in the sector leader companies having strong fundamentals, solid execution track record as well as resilient balance sheet to withstand any cyclical downturns.

Tactical allocation to mid/small caps – Opportunistic allocation to take advantage of any mispriced opportunities or a benevolent risk-on environment.

The fund has a "Growth" and "Quality" oriented investment style, and is focused on companies having a strong visibility of earnings growth coupled with healthy return on capital employed.

OUTLOOK

The outperformance of Indian markets relative to global markets continued in Apr'22. Since Jan'21 the divergence in performance between US and India has been eye-popping. Given that Apr'22 witnessed large FII outflows, the strength of Indian retail flows direct as well as through Mutual Funds was the fulcrum on which this performance was achieved. Over the longer term, earnings growth usually sets the pattern for the market. On that front, the early results, though a mixed bag, are not reporting anything alarming. While earning estimates may be cut for FY23, estimates for FY24 are still largely intact. Aggregate earnings may not appear to have changed much, as upgrades will be limited to a few sectors - Oil & Gas; Metals; Coal & Autos (maybe) the quantum of these upgrades will be equal to or higher than the cuts across a swathe of sectors like consumer staples; discretionary; pharmaceuticals; engineering; EPC, in short users of commodities.

We continue to believe that the elevated commodity prices could lead to either or both of these conditions – a) demand shrinkage, and or b) producers ramping up production, a combination of both should lead to a cooling-off price during the Second half of FY23! Whether this hypothesis works or we have a full-blown inflation scare, will have a material impact on the market move, going forward.

Arpit Kapoor managed this scheme up to 28th February 2022

Ratios calculated on the basis of 3 years history of monthly data.


The above mentioned is the current strategy of the Fund Manager. However, asset allocation and investment strategy shall be within broad parameters of Scheme Information Document.

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.

PORTFOLIO		(30 April 2022)		
Name of the Instrument Equity and Equity related instrument	% to NAV 96.40%	Name of the Instrument Pharmaceuticals & Biotechnology	% to NAV 3.18%	
Banks	29.04%	Divi's Laboratories	1.63%	
HDFC Bank	10.01%	Gland Pharma	1.55%	
ICICI Bank	8.55%	Telecom - Services	2.92%	
State Bank of India	7.25%	Bharti Airtel	2.92%	
Kotak Mahindra Bank	3.22%	Diversified FMCG	2.87%	
IT - Software	13.19%	Hindustan Unilever	2.87%	
Infosys	5.01%	Realty	2.14%	
Tata Consultancy Services	3.02%	Sunteck Realty	2.14%	
Larsen & Toubro Infotech	2.04%	Leisure Services	2.06%	
MphasiS	1.08%	Jubilant Foodworks	2.06%	
Coforge	1.05%	Cement & Cement Products	2.03%	
MindTree	1.00%	UltraTech Cement	2.03%	
Petroleum Products	7.26%	Healthcare Services	1.80%	
Reliance Industries	7.26%	Apollo Hospitals Enterprise	1.80%	
Automobiles	5.60%	Industrial Products	1.73%	
Maruti Suzuki India	2.37%	Bharat Forge	1.73%	
Mahindra & Mahindra	1.63%	Personal Products	1.73%	
Tata Motors	1.60%	Godrej Consumer Products	1.73%	
Chemicals & Petrochemicals	5.26%	Food Products	1.14%	
Anupam Rasayan India	2.32%	Nestle India	1.14%	
SRF	1.48%	Textiles & Apparels	1.07%	
Rossari Biotech	1.47%	Page Industries	1.07%	
Finance	3.88%	IT - Services 1.0		
Bajaj Finance	3.88%	L&T Technology Services 1.019		
Construction	3.83%			
Larsen & Toubro	2.16%	Retailing	0.98%	
PSP Projects	1.67%	Avenue Supermarts	0.98%	
Consumer Durables	3.70%	Corporate Bond	0.004%	
Asian Paints	1.70%	Britannia Industries AAA	A 0.004%	
Voltas	1.01%	Net Cash and Cash Equivalent	3.59%	
Titan Company	0.99%	Grand Total	100.00%	







Scheme risk-o-meter	This product is suitable for investors who are seeking*	Benchmark risk-o-meter
Investors understand that their principal will be at Very High risk	 To create wealth over long term. Investment predominantly in equity and equity related instruments of the large cap companies. *Investors should consult their financial advisers if in doubt about whether the product is suitable for them. 	LOW HOSENITE MORENTELINE LOW HIGH

